SAN DIEGO, CA--(Marketwired - Jun 1, 2015) - Entest BioMedical Inc. (OTC PINK: ENTB) announced today that the Company is currently in discussions to acquire a nanotechnology for the delivery of cancer therapeutics in both animals and humans.
This technology would potentially allow more potent therapeutics to be administered to patients than is currently possible. The reason this is possible is due to the fact that the nanoparticles sequester the drug and allow it to travel throughout the body with minimal toxicity, only releasing the drug directly to the tumor.
A Company spokesman stated: "We are enthusiastic about this potential acquisition. Although Entest has historically focused on veterinary biotechnology, we believe that the acquisition of this nanotechnology would enable us to pursue partnering opportunities in the human market as well as the veterinary market."
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTC PINK: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The Company is also pursuing cancer therapeutics for veterinary application.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.